Margate, NJ -(Business Wire)-June 5, 2002- GeneLink BioSciences, Inc. (OTCBB: GNLK), announced today that the company has received a strong financial review in the Konlin Letter, a monthly financial letter published by Kon-Lin Research & Analysis Corp. of Rocky Point, N.Y. The following are several quotes, " GNLKs patented DNA Collection System is the foundation for all of its assessments. GNLK has the only patented, FDA reviewed, non-invasive, self administered DNA collection system available today." 

"GNLK recently created a break through methodology for SNPs based (Single Nucleotide Polymorphisms) genetic profiling, offering four proprietary new SNPs based assessments: Oxidative Stress (disease and aging), Susceptibility to skin aging, Obesity Susceptibility, and Osteoporosis Susceptibility" 

"As GNLK turns the corner to commercialization, we expect to see a revenue stream with profitability in the not too distant future". 

The letter concludes, "GNLK's proprietary revolutionary genetic assessment products positions GNLK for an explosion in revenues and earnings. First objective $1.75. Ultimate target $4.50 -5.00". 

The GeneLink portion of the Konlin Letter from which these quotes are extracted will be found in its entirety on the GeneLink website at: www.genelink.info. 

About GeneLink BioSciences, Inc. GNLK is positioned to become a leading provider of genetic profiling technologies. It developed a proprietary method for "genetic profiling" (patents pending) and will begin licensing this break through technology to companies that market or manufacture products for the $100 billion plus nutraceutical, skin care, wellness and weight-loss industries. GNLK has FDA clearance and patent issued for its non-invasive DNA Collection Kit. Its DNA bank is located at the University of North Texas Health Science Center at Fort Worth, a 105 year old medical facility that guarantees the DNA storage. 

Forward-Looking Statements: This press release contains certain forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in this press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement. GNLK disclaims any intention or obligation to revise any forward-looking statements whether as a result of new information, future developments or otherwise.

SOURCE: GeneLink BioSciences, Inc.